Online inquiry

IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ753MR)

This product GTTS-WQ753MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ753MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8753MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IBI-101
GTTS-WQ7139MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FG-3019
GTTS-WQ4214MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BIIB029
GTTS-WQ4887MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BYM338
GTTS-WQ13033MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ4289MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB-054
GTTS-WQ12454MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NKTR-214
GTTS-WQ10771MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA M-70
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW